Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
7 hedge funds and large institutions have $19.4M invested in Ayala Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
1% more capital invested
Capital invested by funds: $19.2M → $19.4M (+$209K)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.17M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.5K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$177K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$52.9K |
| 3 |
SCM
Sio Capital Management
New York
|
-$38.2K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.74K |
AYLA Hedge Fund Activity: Q4 2020 in Review
7 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q4 2020, worth a combined $19.4M — up 1.1% from $19.2M a quarter earlier.
Fund positioning in AYLA was balanced in Q4 2020: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $1.17M. The largest seller was Millennium Management, cutting an estimated $177K.
- 7 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $19.4M of Ayala Pharmaceuticals, Inc. Common Stock stock for Q4 2020, up 1.1% quarter-over-quarter.
- 1 fund opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 1 closed out, a net change of 0 holders.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was ARK Investment Management, an estimated $1.17M added.
- The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was Millennium Management, an estimated $177K sold.
Based on aggregated 13F filings for Q4 2020.